Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

24.20 USD +0.10 (+0.41%)
Official Closing Price Updated: 4:20 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,300
Open 24.50
Bid (Size) 23.70 (1)
Ask (Size) 33.00 (4)
Prev. Close 24.10
Today's Range 23.73 - 24.50
52wk Range 18.21 - 35.73
Shares Outstanding 125,949,428
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease; Expanding the Study for Patients 70 Years an
From ACCESSWIRE
Morphosys AG Preliminary Results for the Fiscal Year 2020 Exceeding Guidance
From ACCESSWIRE

Performance

YTD
-15.56%
-15.56%
1 Month
-16.81%
-16.81%
3 Month
-11.78%
-11.78%
6 Month
-20.53%
-20.53%
1 Year
-13.60%
-13.60%

More News

Read More
MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
From ACCESSWIRE
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
From PR Newswire
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From ACCESSWIRE
Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From PR Newswire
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
From ACCESSWIRE
MorphoSys Appoints Sung Lee as Chief Financial Officer
From ACCESSWIRE
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
From ACCESSWIRE
DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
From ACCESSWIRE
Thomas Biegi Joins MorphoSys As Head of Corporate Communications
From ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.